A specific immune transcriptomic profile discriminates chronic kidney disease patients in predialysis from hemodialyzed patients

BMC Medical Genomics

Volumn 6, Issue 1, 2013, Pages

  Zaza, Gianluigi ^a   Granata, Simona ^a   Rascio, Federica ^b   Pontrelli, Paola ^b   Dell'Oglio, Maria Pia ^b   Cox, Sharon Natasha ^b   Pertosa, Giovanni ^b   Grandaliano, Giuseppe ^c   Lupo, Antonio ^a  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c UNIVERSITY OF FOGGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CX3CR1; HLA G ANTIGEN; INTERLEUKIN 15; PENTRAXIN 3;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; EFFECTOR CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE IDENTIFICATION; GENE PROBE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; HUMAN CELL; IMMUNOGENETICS; INTERLEUKIN 15 GENE; LYMPHOCYTE COUNT; MALE; MICROARRAY ANALYSIS; NATURAL KILLER CELL; PENTRAXIN 3 GENE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSCRIPTOMICS; UPREGULATION;

ADULT; C-REACTIVE PROTEIN; DISCRIMINANT ANALYSIS; DOWN-REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORKS; HLA-G ANTIGENS; HUMANS; INTERLEUKIN-15; KIDNEY FAILURE, CHRONIC; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; RECEPTORS, CHEMOKINE; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; SERUM AMYLOID P-COMPONENT; SEVERITY OF ILLNESS INDEX; UP-REGULATION;

EID: 84877302923     PISSN: None     EISSN: 17558794     Source Type: Journal    
DOI: 10.1186/1755-8794-6-17     Document Type: Article

References (73)

1. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: third National Health and Nutrition Examination Survey. Coresh J, Astor BC, Greene T, Am J Kidney Dis 2003 41 1 12 12500213 (Pubitemid 36043346)
2. The burden of chronic kidney disease. Hamer RA, El Nahas AM, BMJ 2006 332 563 564 10.1136/bmj.332.7541.563 16528062 (Pubitemid 44365753)
3. ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends. Grassmann A, Gioberge S, Moeller S, Nephrol Dial Transplant 2005 20 2587 2593 10.1093/ndt/gfi159 16204281 (Pubitemid 41672250)
4. US Renal Data System, US Renal Data System 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States 2010
5. Chronic kidney disease: effects on the cardiovascular system. Schiffrin EL, Lipman ML, Mann JF, Circulation 2007 116 85 97 10.1161/CIRCULATIONAHA.106. 678342 17606856 (Pubitemid 47016250)
6. CKD progression and mortality among older patients with diabetes. Patel UD, Young EW, Ojo AO, Hayward RA, Am J Kidney Dis 2005 46 406 414 10.1053/j.ajkd.2005.05.027 16129201 (Pubitemid 41208175)
7. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. National Kidney Foundation, Am J Kidney Dis 2002 39 1 S266 11904577
8. Exploring metabolic dysfunction in chronic kidney disease. Slee AD, Nutr Metab (Lond) 2012 9 36 10.1186/1743-7075-9-36
9. Mitochondrial dysregulation and oxidative stress in patients with chronic kidney disease. Granata S, Zaza G, Simone S, BMC Genomics 2009 10 388 10.1186/1471-2164-10-388 19698090
10. Dialysis-related systemic microinflammation is associated with specific genomic patterns. Zaza G, Pontrelli P, Pertosa G, Nephrol Dial Transplant 2008 23 1673 1681 10.1093/ndt/gfm804 18048420 (Pubitemid 351767731)
11. Aspects of immune dysfunction in end-stage renal disease. Kato S, Chmielewski M, Honda H, Clin J Am Soc Nephrol 2008 3 1526 1533 10.2215/CJN.00950208 18701615
12. Characteristics and causes of immune dysfunction related to uremia and dialysis. Hauser AB, Stinghen AE, Kato S, Perit Dial Int 2008 28 183 S187 18552253
13. Immunological basis of inflammation in dialysis. Amore A, Coppo R, Nephrol Dial Transplant 2002 17 16 24 12386276 (Pubitemid 34918874)
14. Review on uremic toxins: classification, concentration, and interindividual variability. Vanholder R, De Smet R, Glorieux G, Kidney Int 2003 63 1934 1943 10.1046/j.1523-1755.2003.00924.x 12675874 (Pubitemid 36513344)
15. Immunologic function and survival in hemodialysis patients. Kimmel PL, Phillips TM, Simmens SJ, Kidney Int 1998 54 236 244 10.1046/j.1523-1755.1998. 00981.x 9648084 (Pubitemid 28288040)
16. IL-10, IL-6, and TNF-a: Central factors in the altered cytokine network of uremia-The good, the bad, and the ugly. Stevinkel P, Ketteler M, Johnson RJ, Kidney Int 2005 67 1216 1233 10.1111/j.1523-1755.2005.00200.x 15780075 (Pubitemid 40463099)
17. Uremia. Haddy FJ, Meyer TW, N Engl J Med 2007 357 1316 1325 10.1056/NEJMra071313 17898101 (Pubitemid 47481454)
18. New insights in dialysis membrane biocompatibility: relevance of adsorption properties and heparin binding. Chanard J, Lavaud S, Nephrol Dial Transplant 2003 18 252 257 10.1093/ndt/18.2.252 12543877 (Pubitemid 36181673)
19. Cytokines and bioincompatibility. Gesualdo L, Pertosa G, Grandaliano G, Nephrol Dial Transplant 1998 13 1622 1626 10.1093/ndt/13.7.1622 9681699 (Pubitemid 28306783)
20. Haemodialysis, atherosclerosis and inflammation-identifying molecular mechanisms of chronic vascular disease in ESRD patients. Walter R, Mischak H, Haller H, Nephrol Dial Transplant 2002 17 24 29 12091628 (Pubitemid 34450114)
21. Fluid balance, dry weight, and blood pressure in dialysis. Charra B, Hemodial Int 2007 11 21 31 10.1111/j.1542-4758.2007.00198.x 17257351 (Pubitemid 47491295)
22. Metabolic disorders in patients with chronic kidney failure. Cibulka R, Racek J, Physiol Res 2007 56 697 705 17298212
23. Induction of tumor necrosis factor during extracorporeal blood purification. Lonnemann G, Meer JW, Cannon JG, N Engl J Med 1987 317 963 964 3627217 (Pubitemid 17147945)
24. Interleukin-8 in chronic renal failure and dialysis patients. Nakanishi I, Moutabarrik A, Okada N, Nephrol Dial Transplant 1994 9 1435 1442 7816257 (Pubitemid 24310287)
25. Activation of complement by hemodialysis membranes: Polyacrylonitrile binds more C3a than cuprophan. Alfred K, Cheung AK, Parker CJ, Kidney Int 1990 37 1055 1059 10.1038/ki.1990.85 2342244 (Pubitemid 20106665)
26. Initiation of hemodialysis treatment leads to improvement of T-cell activation in patients with end-stage renal disease. Kaul H, Girndt M, Sester U, Am J Kidney Dis 2000 35 611 616 10.1016/S0272-6386(00)70006-0 10739780 (Pubitemid 30185504)
27. Biocompatibility of dialysis fluid for online HDF. Tomo T, Shinoda T, Contrib Nephrol 2011 168 89 98 20938128
28. The initial vascular access type contributes to inflammation in incident hemodialysis patients. Sachdeva M, Hung A, Kovalchuk O, Int J Nephrol 2012 2012 917465 22121485
29. Vascular access in haemodialysis patients: a modifiable risk factor for bacteraemia and death. Thomson PC, Stirling CM, Geddes CC, QJM 2007 100 415 422 10.1093/qjmed/hcm040 17526532 (Pubitemid 47062893)
30. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Golub TR, Slonim DK, Tamayo P, Science 1999 286 531 537 10.1126/science.286.5439.531 10521349
31. Statistical significance for genomewide studies. Storey JD, Tibshirani R, Proc Natl Acad Sci USA 2003 100 9440 9445 10.1073/pnas.1530509100 12883005 (Pubitemid 37033947)
32. Disturbances of acquired immunity in hemodialysis patients. Eleftheriadis T, Antoniadi G, Liakopoulos V, Semin Dial 2007 20 440 451 10.1111/j.1525-139X. 2007.00283.x 17897251
33. Vitamin D receptor activators and response to injury in kidney diseases. Eleftheriadis T, Antoniadi G, Liakopoulos V, J Nephrol 2010 23 514 524 20540037
34. Erythropoietin attenuated vascular dysfunction and inflammation by inhibiting NADPH oxidase-derived superoxide production in nitric oxide synthase-inhibited hypertensive rat aorta. Toba H, Kojima Y, Wang J, Eur J Pharmacol 2012 691 190 197 10.1016/j.ejphar.2012.07.018 22796671
35. Impact of iron treatment on immune effector function and cellular iron status of circulating monocytes in dialysis patients. Sonnweber T, Theurl I, Seifert M, Nephrol Dial Transplant 2011 26 977 987 10.1093/ndt/gfq483 20826742
36. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Garlanda C, Bottazzi B, Bastone A, Annu Rev Immunol 2005 23 337 366 10.1146/annurev.immunol.23.021704.115756 15771574 (Pubitemid 40563173)
37. Persisting high levels of plasma pentraxin 3 over the first days after severe sepsis and septic shock onset are associated with mortality. Mauri T, Bellani G, Patroniti N, Intensive Care Med 2010 36 621 629 10.1007/s00134-010- 1752-5 20119647
38. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Latini R, Maggioni AP, Peri G, Circulation 2004 110 2349 2354 10.1161/01.CIR.0000145167.30987.2E 15477419 (Pubitemid 39407338)
39. Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions. Savchenko A, Imamura M, Ohashi R, J Pathol 2008 215 48 55 10.1002/path.2314 18220316 (Pubitemid 351619875)
40. Pentraxin 3 is elevated in haemodialysis patients and is associated with cardiovascular disease. Boehme M, Kaehne F, Kuehne A, Nephrol Dial Transplant 2007 22 2224 2229 10.1093/ndt/gfl747 17496115 (Pubitemid 47244700)
41. Changes in circulating biomarkers during a single hemodialysis session. Yamamoto T, Nascimento MM, Hayashi SY, Hemodial Int 2012 in press
42. Overexpression of interleukin (IL)-7 leads to IL-15-independent generation of memory phenotype CD8+ T cells. Kieper WC, Tan JT, Bondi-Boyd B, J Exp Med 2002 195 1533 1539 10.1084/jem.20020067 12070281 (Pubitemid 34666067)
43. Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8+ cells but are not required for memory phenotype CD4+ cells. Tan JT, Ernst B, Kieper WC, J Exp Med 2002 195 1523 1532 10.1084/jem.20020066 12070280 (Pubitemid 34666066)
44. Tyrosine phosphorylation and activation of STAT5, STAT3, and Janus kinases by interleukins 2 and 15. Johnston JA, Bacon CM, Finbloom DS, Proc Natl Acad Sci USA 1995 92 8705 8709 10.1073/pnas.92.19.8705 7568001
45. IL-15 is an essential mediator of peripheral NK-cell homeostasis. Ranson T, Vosshenrich CA, Corcuff E, Blood 2003 101 4887 4893 10.1182/blood-2002-11- 3392 12586624 (Pubitemid 36857750)
46. The role of HLA-G in immunity and hematopoiesis. Carosella ED, Gregori S, Rouas-Freiss N, Cell Mol Life Sci 2011 68 353 368 10.1007/s00018-010-0579-0 21116680
47. Biology and functions of human leukocyte antigen-G in health and sickness. LeMaoult J, Le Discorde M, Rouas-Freiss N, Tissue Antigens 2003 62 273 284 10.1034/j.1399-0039.2003.00143.x 12974794 (Pubitemid 37204582)
48. HLA-G protein processing and transport to the cell surface. Moreau P, Rousseau P, Rouas-Freiss N, Cell Mol Life Sci 2002 59 1460 1466 10.1007/s00018-002-8521-8 12440768 (Pubitemid 35239302)
49. HLA-G and immune tolerance in pregnancy. Hunt JS, Petroff MG, McIntire RH, FASEB J 2005 19 681 693 10.1096/fj.04-2078rev 15857883 (Pubitemid 40617373)
50. Identification of a thymic epithelial cell subset sharing expression of the class Ib HLA-G molecule with fetal trophoblasts. Crisa L, McMaster MT, Ishii JK, J Exp Med 1997 186 289 298 10.1084/jem.186.2.289 9221758 (Pubitemid 27328029)
51. Endothelial cells in chorionic fetal vessels of first trimester placenta express HLA-G. Blaschitz A, Lenfant F, Mallet V, Eur J Immunol 1997 27 3380 3388 10.1002/eji.1830271237 9464826 (Pubitemid 28018035)
52. Expression of HLA-G in human mononuclear phagocytes and selective induction by IFN-γ Yang Y, Chu W, Geraghty DE, J Immunol 1996 156 4224 4231 8666791 (Pubitemid 26165819)
53. Implication of HLA-G molecule in heart-graft acceptance. Lila N, Carpentier A, Amrein C, Lancet 2000 355 2138 10.1016/S0140-6736(00)02386-2 10902633 (Pubitemid 30364668)
54. HLA-G in transplantation: a relevant molecule for inhibition of graft rejection? Rouas-Freiss N, LeMaoult J, Moreau P, Am J Transplant 2003 3 11 16 10.1034/j.1600-6143.2003.30103.x 12492704 (Pubitemid 36306817)
55. HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Paul P, Rouas-Freiss N, Khalil-Daher I, Proc Natl Acad Sci USA 1998 95 4510 4515 10.1073/pnas.95.8.4510 9539768 (Pubitemid 28207943)
56. Modulation of HLA-G antigens expression by human cytomegalovirus: specific induction in activated macrophages harboring human cytomegalovirus infection. Onno M, Pangault C, Le Friec G, J Immunol 2000 164 6426 6434 10843698 (Pubitemid 30408825)
57. Soluble HLA-G in rheumatoid arthritis. Verbruggen LA, Rebmann V, Demanet C, Hum Immunol 2006 67 561 567 10.1016/j.humimm.2006.03.023 16916651 (Pubitemid 44205319)
58. HLA-G gene repression is reversed by demethylation. Moreau P, Mouillot G, Rousseau P, Proc Natl Acad Sci USA 2003 100 1191 1196 10.1073/pnas.0337539100 12552087 (Pubitemid 36183978)
59. Expression of HLA G in human tumors is not a frequent event. Real LM, Cabrera T, Collado A, Int J Cancer 1999 81 512 518 10.1002/(SICI)1097- 0215(19990517)81:4<512::AID-IJC2>3.0.CO;2-O 10225437 (Pubitemid 29203045)
60. Expression and regulation of non-classical HLA-G in renal cell carcinoma. Dunker K, Schlaf G, Bukur J, Tissue Antigens 2008 72 137 148 10.1111/j.1399-0039.2008.01090.x 18721274 (Pubitemid 352009822)
61. Human myelomonocytic cells express an inhibitory receptor for classical and nonclassical MHC class I molecules. Colonna M, Samaridis J, Cella M, J Immunol 1998 160 3096 3100 9531263 (Pubitemid 28164696)
62. A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. Rajagopalan S, Long EO, J Exp Med 1999 189 1093 1100 10.1084/jem.189.7.1093 10190900 (Pubitemid 29169826)
63. HLA-G2, -G3, and -G4 isoforms expressed as nonmature cell surface glycoproteins inhibit NK and antigen-specific CTL cytolysis. Riteau B, Rouas-Freiss N, Menier C, J Immunol 2001 166 5018 5026 11290782 (Pubitemid 32280714)
64. Inhibition of human gamma delta T-cell antitumoral activity through HLA-G: implications for immunotherapy of cancer. Lesport E, Baudhuin J, Sousa S, Cell Mol Life Sci 2011 68 3385 3399 10.1007/s00018-011-0632-7 21337044
65. HLA-G inhibits the allogeneic proliferative response. Riteau B, Menier C, Khalil-Daher I, J Reprod Immunol 1999 43 203 211 10.1016/S0165-0378(99)00034-0 10479056 (Pubitemid 29349684)
66. HLA-G-expressing antigen-presenting cells induce immunosuppressive CD4+ T cells. LeMaoult J, Krawice-Radanne I, Dausset J, Carosella ED, Proc Natl Acad Sci USA 2004 101 7064 7069 10.1073/pnas.0401922101 15103024 (Pubitemid 38596443)
67. Tolerization of dendritic cells by HLA-G. Ristich V, Liang S, Zhang W, Eur J Immunol 2005 35 1133 1142 10.1002/eji.200425741 15770701 (Pubitemid 40542220)
68. Natural Killer cell alterations correlate with loss of renal function and dialysis duration in uraemic patients. Vacher-Coponat H, Brunet C, Lyonnet L, Nephrol Dial Transplant 2008 23 1406 1414 18029366 (Pubitemid 351767470)
69. Cytokine production and cytotoxicity of lymphocytes in patients on maintenance short- or long-term haemodialysis. Hayakawa M, Hatano T, Sunabe T, Nephrol Dial Transplant 1994 9 655 661 7970092 (Pubitemid 24192952)
70. Fractalkine in vascular biology: from basic research to clinical disease. Umehara H, Bloom ET, Okazaki T, Arterioscler Thromb Vasc Biol 2004 24 34 40 10.1161/01.ATV.0000095360.62479.1F 12969992 (Pubitemid 38082409)
71. CX3C-chemokine, fractalkine-enhanced adhesion of THP-1 cells to endothelial cells through integrin-dependent and -independent mechanisms. Goda S, Imai T, Yoshie O, J Immunol 2000 164 4313 4320 10754331 (Pubitemid 30215094)
72. Fractalkine, a novel chemokine in rheumatoid arthritis and in rat adjuvant-induced arthritis. Ruth JH, Volin MV, Haines GK 3rd, Arthritis Rheum 2001 44 1568 1581 10.1002/1529-0131(200107)44:7<1568::AID-ART280>3.0.CO;2- 1 11465708 (Pubitemid 32642219)
73. Upregulation of fractalkine and its receptor, CX3CR1, is associated with coronary plaque rupture in patients with unstable angina pectoris. Ikejima H, Imanishi T, Tsujioka H, Circ J 2010 74 337 345 10.1253/circj.CJ-09-0484 20019415